FUROSEMIDE- furosemide tablet

Χώρα: Ηνωμένες Πολιτείες

Γλώσσα: Αγγλικά

Πηγή: NLM (National Library of Medicine)

Αγόρασέ το τώρα

Αρχείο Π.Χ.Π. Αρχείο Π.Χ.Π. (SPC)
09-04-2019

Δραστική ουσία:

FUROSEMIDE (UNII: 7LXU5N7ZO5) (FUROSEMIDE - UNII:7LXU5N7ZO5)

Διαθέσιμο από:

REMEDYREPACK INC.

INN (Διεθνής Όνομα):

FUROSEMIDE

Σύνθεση:

FUROSEMIDE 20 mg

Οδός χορήγησης:

ORAL

Τρόπος διάθεσης:

PRESCRIPTION DRUG

Θεραπευτικές ενδείξεις:

Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone. Furosemide is contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide.

Περίληψη προϊόντος:

Furosemide tablets, USP, for oral administration, are available as: 20 mg: round, white, scored tablets, debossed GG 21 on one side and plain on the reverse side, and supplied as: NDC 0781-1818-01 bottles of 100 NDC 0781-1818-05 bottles of 500 NDC 0781-1818-10 bottles of 1000 40 mg: round, white, scored tablets, debossed GG 201 on one side and plain on the reverse side, and supplied as: NDC 0781-1966-60 bottles of 60 NDC 0781-1966-01 bottles of 100 NDC 0781-1966-05 bottles of 500 NDC 0781-1966-10 bottles of 1000 80 mg: round, white, scored tablets, debossed GG 80 on one side and plain on the reverse side, and supplied as: NDC 0781-1446-01 bottles of 100 NDC 0781-1446-05 bottles of 500 Exposure to light might cause a slight discoloration. Discolored tablets should not be dispensed. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container.

Καθεστώς αδειοδότησης:

New Drug Application

Αρχείο Π.Χ.Π.

                                FUROSEMIDE- FUROSEMIDE TABLET
REMEDYREPACK INC.
----------
FUROSEMIDE TABLETS, USP
RX ONLY
WARNING
FUROSEMIDE IS A POTENT DIURETIC WHICH, IF GIVEN IN EXCESSIVE AMOUNTS,
CAN LEAD TO A PROFOUND
DIURESIS WITH WATER AND ELECTROLYTE DEPLETION. THEREFORE, CAREFUL
MEDICAL SUPERVISION IS REQUIRED
AND DOSE AND DOSE SCHEDULE MUST BE ADJUSTED TO THE INDIVIDUAL
PATIENT’S NEEDS _[SEE DOSAGE AND_
_ADMINISTRATION]_.
DESCRIPTION
Furosemide is a diuretic which is an anthranilic acid derivative.
Chemically, it is 4-chloro- _N_-furfuryl-
5-sulfamoylanthranilic acid. Furosemide is a white to off-white
odorless crystalline powder. It is
practically insoluble in water, sparingly soluble in alcohol, freely
soluble in dilute alkali solutions and
insoluble in dilute acids.
The structural formula is as follows:
Furosemide is available in 20 mg, 40 mg and 80 mg tablets for oral
administration.
Inactive ingredients include lactose monohydrate, magnesium stearate,
pregelatinized starch and starch
(corn).
Meets USP Dissolution Test 1.
CLINICAL PHARMACOLOGY
Investigations into the mode of action of furosemide have utilized
micropuncture studies in rats, stop
flow experiments in dogs and various clearance studies in both humans
and experimental animals. It has
been demonstrated that furosemide inhibits primarily the absorption of
sodium and chloride not only in
the proximal and distal tubules but also in the loop of Henle. The
high degree of efficacy is largely due
to the unique site of action. The action on the distal tubule is
independent of any inhibitory effect on
carbonic anhydrase and aldosterone.
Recent evidence suggests that furosemide glucuronide is the only or at
least the major
biotransformation product of furosemide in man. Furosemide is
extensively bound to plasma proteins,
mainly to albumin. Plasma concentrations ranging from 1 to 400 mcg/mL
are 91 to 99% bound in healthy
individuals. The unbound fraction averages 2.3 to 4.1% at therapeutic
concentrations.
The onset of diuresis following oral administration is within 1 hour.
The
                                
                                Διαβάστε το πλήρες έγγραφο
                                
                            

Αναζήτηση ειδοποιήσεων που σχετίζονται με αυτό το προϊόν

Προβολή ιστορικού εγγράφων